Global and United States Type-1 Diabetes Treatment Market Report & Forecast 2022-2028

Type-1 diabetes accounts for 5%–10% of all diabetes cases worldwide. Failure to produce insulin is the cause of this type of diabetes. 
Market Analysis and Insights: Global and United States Type-1 Diabetes Treatment Market
This report focuses on global and United States Type-1 Diabetes Treatment market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global Type-1 Diabetes Treatment market size is estimated to be worth US$ 5401.7 million in 2022 and is forecast to a readjusted size of US$ 7034.4 million by 2028 with a CAGR of 4.5% during the review period. Fully considering the economic change by this health crisis, by Type, Rapid-Acting Insulin accounting for % of the Type-1 Diabetes Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Hospitals & Clinics was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
In United States the Type-1 Diabetes Treatment market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period.
Global Type-1 Diabetes Treatment Scope and Market Size
Type-1 Diabetes Treatment market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Type-1 Diabetes Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Type-1 Diabetes Treatment market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Rapid-Acting Insulin
Short-Acting Insulin
Others
Segment by Application
Hospitals & Clinics
Academic & Research Institutes
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Astellas Pharma
Merck
Eli Lilly
Novo Nordisk
Sanofi
AstraZeneca
Boehringer Ingelheim GmbH
Novartis
Pfizer Inc.
Abbott Laboratories
Mannkind Corporation
Braun Melsungen AG
Macrogenics, Inc.